CRISPR Medicine

Gamida Cell

Main focus: Gene editing for the development of next-generation cell therapies

Company stage: Clinical

Diseases: Non-Hodgkin lymphoma (NHL), multiple myeloma, solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:GMDA)

Location: Boston, MA, USA

Website: https://www.gamida-cell.com

Pipeline: https://www.gamida-cell.com/our-rd/

Partners: Editas Medicine


Gamida Cell is focusing on the development of next-generation cell therapies to treat cancer. The company has multiple pre-clinical programmes where CRISPR-Cas9 is being used to knock out important targets to improve potency, persistence and safety.

See the full view ...